AngioDynamics

AngioDynamics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of AngioDynamics (ANGO) as of Sep 21, 2026 is -1.38 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 42.93 % — a change of -103.22% (lower).

FCF Conversion

-1.38 %

YoY

-103.22%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of AngioDynamics is 2026 -1.38 % . FCF Conversion Rate (FCF/EBITDA) of AngioDynamics was 2025 42.93 % . It decreases by -103.22% lower compared to the previous year.

The AngioDynamics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
55.95 USD
Jan 1, 2020
13.27 USD
Jan 1, 2021
-59.93 USD
Jan 1, 2022
43.29 USD
Jan 1, 2023
8.15 USD
Jan 1, 2024
18.40 USD
Jan 1, 2025
42.93 USD
Jan 1, 2026
-1.38 USD
The AngioDynamics FCF Conversion history
YEARFCF ConversionYoY
-1.38 %-103.22%
42.93 %+133.26%
18.40 %+125.81%
8.15 %-81.17%
43.29 %-172.23%
-59.93 %-551.47%
13.27 %-76.28%
55.95 %-75.71%
230.37 %-130.80%
-747.93 %+722.83%
-90.90 %-76.22%
-382.20 %-174.29%
514.44 %
Access this data via the Eulerpool API

AngioDynamics Stock analysis

What does AngioDynamics do? AngioDynamics Inc is a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company was founded in 1988 and is headquartered in Latham, New York. Over the years, AngioDynamics has evolved into a conglomerate through several acquisitions and partnerships, specializing in various areas. The key divisions include Vascular Access Solutions, Oncology Solutions, and Peripheral Vascular Solutions. AngioDynamics focuses on developing and manufacturing innovative technologies that improve medical care and promote patient health. The company develops and distributes a wide range of medical devices and procedures to treat diseases such as cancer, venous diseases, and thrombosis. In the Vascular Access Solutions division, AngioDynamics offers a wide range of devices for establishing vascular access, which are necessary for the treatment of serious illnesses. This includes port systems and catheters that facilitate access to the body's vascular system. AngioDynamics' Oncology Solutions provide targeted cancer treatment options, including ultrasound-controlled radiofrequency ablation systems and fusion biopsy systems. The development of innovative diagnostic and treatment options is a focus of AngioDynamics. A majority of AngioDynamics' products are in the Peripheral Vascular Solutions division. Here, the company develops devices and procedures for the treatment of peripheral vascular diseases such as varicose veins or chronic venous insufficiency. This includes procedures like laser and radiofrequency treatments that can be performed minimally invasively. AngioDynamics has gained an excellent reputation in the medical industry due to its high-quality products, innovative technologies, and close collaboration with medical professionals. The company places great emphasis on providing optimal care to every patient and therefore serves hospitals, clinics, and medical practices worldwide. Over the years, AngioDynamics has become a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company has built a broad customer base worldwide and has become an important player in the medical industry due to the quality and innovation of its products. AngioDynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AngioDynamics stock

FCF Conversion Rate (FCF/EBITDA) of AngioDynamics is -1.38 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of AngioDynamics changed from 42.93 % to -1.38 %, representing a -103.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) AngioDynamics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s AngioDynamics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — AngioDynamics

All Key Metrics — AngioDynamics